New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
05:55 EDTADUS, ADUS, ATRS, ATRS, BGMD, BGMD, DSCO, DSCO, EXPR, EXPR, GSOL, GSOL, KOPN, KOPN, PERI, PERI, SNSS, SNSSCompanies reporting Before the Market Open on Wednesday, March 13
Notable companies reporting before the opening bell on Wednesday include Addus Homecare (ADUS), Antares Pharma (ATRS), BG Medicine (BGMD), Discovery Laboratories (DSCO), Express (EXPR), Global Sources (GSOL), Kopin (KOPN), Perion Network (PERI), and Sunesis Pharmaceuticals (SNSS).
News For ADUS;ATRS;BGMD;DSCO;EXPR;GSOL;KOPN;PERI;SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
09:03 EDTEXPRExpress, Abercrombie & Fitch spring outlook positive, says BMO Capital
Subscribe for More Information
08:25 EDTEXPRUBS to hold a trip
Spring Mall Crawl visits various companies in the malls in Atlanta, Georgia on February 11.
February 9, 2016
12:15 EDTADUSAddus HomeCare served with 'whistleblower' suit over referrals
Subscribe for More Information
February 8, 2016
07:05 EDTADUSAddus HomeCare closes acquisition of South Shore Home Health Services
Addus HomeCare announced that it has closed the previously announced acquisition of South Shore Home Health Services, a New York state-licensed home care services agency primarily providing personal care services. South Shore, headquartered on Long Island, currently serves Suffolk, Nassau, Queens and Westchester counties. Addus expects that the acquisition of South Shore, which produced revenues for 2015 of approximately $52M, will be accretive to the Company's 2016 financial results.
February 1, 2016
16:05 EDTDSCODiscovery Labs initiates AEROSURF phase 2b clinical trial
Discovery Labs said that based on the safety and tolerability profile observed to date in the phase 2a clinical program, the company has initiated the AEROSURF phase 2b clinical trial in premature infants 26 to 32 week gestational age receiving nasal continuous positive airway pressure for respiratory distress syndrome. The trial is a multicenter, randomized, controlled study with masked treatment assignment in approximately 240 premature infants and is designed to evaluate the safety and tolerability of aerosolized KL4 surfactant administered in two dose groups, compared to infants receiving nCPAP alone. The following endpoints will be evaluated: time to nCPAP failure, incidence of nCPAP failure and physiological parameters indicating the effectiveness of lung function. The trial is expected to be conducted in up to 60 clinical sites in the United States, Canada, Europe and Latin America. Enrollment is beginning with premature infants 29 to 32 weeks GA, and will include premature infants 26 to 28 weeks GA after completion of the ongoing phase 2a clinical trial in this age group. The xompany anticipates completing enrollment for the phase 2b clinical trial by the end of 2016 and releasing top-line results in the first quarter of 2017. As of December 31, 2015, the xompany had cash and cash equivalents of $38.7M, an amount it anticipates is sufficient to support the AEROSURF phase 2 clinical program and fund operations through Q1 of 2017.
16:03 EDTDSCODiscovery Labs announces resignation of CEO John Cooper
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use